feedback

Conference Series: Part 2 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Gene splicing modifiers
  • Gene replacement therapy MOA
  • Clinical trial results

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.